Organogenesis Holdings Inc. (ORGO) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several negative aspects: declining net product revenue, a significant EBITDA loss, and reduced cash reserves. Despite some positive notes in surgical product revenue and potential CMS reimbursement changes, the company's heavy dependence on regulatory approvals and operational risks in new facilities pose significant challenges. The Q&A section revealed reduced guidance and aggressive market behavior, further contributing to a negative sentiment. Overall, these factors suggest a negative stock price movement in the short term.
Key Financial Performance
Net Product Revenue (Q2 2025) $100.8 million, down 23% year-over-year. The decline was attributed to disruptions in customer demand and ordering patterns due to the delay in the effective date of the final LCD for skin substitute grafts and cellular tissue-based products.
Advanced Wound Care Net Product Revenue (Q2 2025) $92.7 million, down 25% year-over-year. The decline was due to increased competitive pricing tactics and the delay in the effective date of the LCD.
Surgical & Sports Medicine Products Revenue (Q2 2025) $8.1 million, up 16% year-over-year. Growth was driven by better-than-expected performance in this segment.
Gross Profit (Q2 2025) $73.1 million or 73% of net product revenue, compared to 78% in the prior year. The decrease was due to lower revenue over fixed costs and the expiration of excess product resulting from the delayed LCD implementation.
Operating Expenses (Q2 2025) $113.6 million, down 21% year-over-year. The decrease was driven by lower research and development and SG&A expenses, as well as a reduction in nonrecurring costs.
Operating Loss (Q2 2025) $12.6 million, compared to $13.9 million in the prior year. The improvement was due to reduced operating expenses.
Adjusted EBITDA Loss (Q2 2025) $3.6 million, compared to adjusted EBITDA income of $15.6 million in the prior year. The decline was due to lower revenue and gross profit.
Cash, Cash Equivalents, and Restricted Cash (June 30, 2025) $73.7 million, compared to $136.2 million as of December 31, 2024. The decrease was due to operational cash outflows.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ReNu Program: The company remains on track for submission for ReNu by the end of 2025. This product targets over 30 million Americans suffering from symptomatic knee osteoarthritis. All patients completed the second Phase III study, and top-line data results are expected in September 2025.
Dermagraft and TransCyte: The company is reintroducing Dermagraft for DFUs and TransCyte for deep second- and third-degree burns. These are PMA-approved products.
FortiShield: A new biosynthetic transitional wound matrix for second-degree burns and surgical wounds is being introduced.
Medicare Policy Changes: CMS proposed a new payment approach for skin substitutes, including a per square centimeter payment methodology based on FDA classification. This is expected to stabilize the market and encourage innovation.
Market Positioning: The company is positioned to lead the market with a comprehensive portfolio, including products from all FDA classifications, and is advocating for health policy reforms to ensure patient access to appropriate products.
Biomanufacturing Expansion: The company expanded its biomanufacturing capabilities at a new facility in Smithfield, Rhode Island, which will support the production of Dermagraft, TransCyte, and FortiShield.
Clinical Data Submission: The company plans to submit clinical data supporting PuraPly AM for DFU and Affinity for VLU to the MACs by November 1, 2025.
Focus on Innovation: The company is investing in developing advanced regenerative technologies to address chronic wounds and reduce healthcare costs.
Advocacy for Policy Reform: Organogenesis has been actively engaging with CMS and stakeholders to refine proposed rules and expand patient access to therapies while reducing Medicare costs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Advanced Wound Care revenue decline: The company's Advanced Wound Care net product revenue for Q2 2025 decreased by 25%, reflecting disruptions in customer demand and ordering patterns due to the delay in the effective date of the final LCD for skin substitute grafts and cellular tissue-based products. This delay also led to increased aggressive pricing strategies from competitors.
Gross margin pressure: Gross profit margin declined to 73% from 78% in the prior year, primarily due to lower revenue over fixed costs and the expiration of excess product caused by the delayed LCD implementation.
Increased competition: The delay in the LCD implementation has fueled aggressive pricing strategies from competitors, creating a challenging market environment.
Regulatory uncertainty: The company faces regulatory uncertainty as it awaits the finalization of CMS's proposed Medicare payment rules for 2026, which could significantly impact the market dynamics for skin substitutes.
Cash position decline: The company's cash, cash equivalents, and restricted cash decreased from $136.2 million at the end of 2024 to $73.7 million as of June 30, 2025, raising concerns about financial flexibility.
Profitability challenges: The company reported an adjusted EBITDA loss of $3.6 million for Q2 2025, compared to an adjusted EBITDA income of $15.6 million in the prior year, indicating profitability challenges.
Operational risks in new facilities: The expansion of biomanufacturing capabilities at the new Smithfield facility introduces operational risks, including potential delays or cost overruns.
Dependence on regulatory approvals: The company's growth plans heavily depend on regulatory approvals, such as the BLA submission for ReNu and the reintroduction of Dermagraft and TransCyte, which could face delays or rejections.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Revenue Guidance: The company expects net revenue of between $480 million and $510 million, representing a year-over-year change in the range of flat to an increase of 6%. This includes net revenue from Advanced Wound Care products between $450 million and $475 million (a decline of 1% to an increase of 5%) and net revenue from Surgical & Sports Medicine products between $30 million and $35 million (an increase of 6% to 23%).
Profitability and EBITDA Guidance: The company expects GAAP net loss in the range of $6.4 million to net income of $16.4 million, EBITDA in the range of $6.2 million to $37 million, non-GAAP adjusted net income in a range of $5.5 million to $28.3 million, and adjusted EBITDA in the range of $31.1 million to $61.9 million.
Gross Margins: Gross margins are expected to be in the range of approximately 74% to 76%, reflecting the impact of product mix shift in in-licensed brands in the second half of 2025.
Third Quarter Revenue: Revenue is expected to be in the range of approximately $130 million to $145 million.
Operating Expenses: GAAP operating expenses, excluding cost of goods sold, are expected to be flat to up 1% year-over-year. Non-GAAP operating expenses will increase 3% to 4% year-over-year, compared to a range of 5% to 7% previously.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cumulative dividend impact: Net loss to common includes the impact of both the cumulative dividend and the noncash accretion to redemption value on our convertible preferred stock.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are your thoughts on the CMS proposal for 2026 and its impact on ORGO?
A:The CMS proposal for 2026 is seen as a transformational event for the industry and a significant opportunity for Organogenesis. The proposal sets reimbursement at $125 per square centimeter, which is a substantial increase from the current $30 for Apligraf. This change eliminates financial disincentives and levels the playing field for products like Apligraf and Dermagraft. The company expects increased utilization and market share for its products, especially in the HOPD market. However, aggressive pricing and discounting are anticipated in the market through the end of 2025.
Q:How does the guidance reduction for the year account for aggressive market behavior?
A:The guidance reduction of $12.5 million at the midpoint reflects the company's anticipation of aggressive pricing and discounting in the market. Despite challenges, the company is confident in its recently launched products and expects them to contribute significantly in the back half of the year. The guidance range was narrowed, and the company is confident in achieving the low end of the range based on strong momentum exiting Q2.
Q:What is the timing for the reintroduction of Dermagraft?
A:The company expects to launch Dermagraft in the second half of 2027.
Q:What are your thoughts on ReNu's positioning within the knee OA treatment landscape?
A:ReNu is positioned as a robust product with strong data, particularly in treating KL4 patients, who performed similarly to KL3s and KL2s in studies. This differentiates ReNu from existing injectable options like hyaluronic acid and steroids, and the company is optimistic about its competitive potential.
Q:What drove the strength in the Surgical & Sports side of the business, and how do you expect this momentum to continue?
A:The strength in the Surgical & Sports side was driven by key products in the portfolio and the implementation of hybrid rep situations, where reps span across both Wound Care and Surgical. The segment saw strong performance, with 16% growth in the quarter and 13% for the half. The company expects this momentum to continue.
Q:Review of Unclear Management Responses
A:Management avoided providing a specific timeline for the reintroduction of Dermagraft initially, citing competitive reasons, but later mentioned a launch expected in the second half of 2027.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASP
DFUs
Dermagraft
FDA classification
PMA product
ReNu
Research Division
Rhode Island
Smithfield
Surgical Sports
access product
access therapy
capacity
cost
date LCD
degree burn
delay date
engine
expansion
grant
healing technology
life
moment industry
outpatient
patient access
payment approach
payment system
people
portfolio
reform access
rule
space
spending
tissue
treatment degree
year
ORGO Transcript
Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call indicates strong financial performance with a 10% revenue increase and a 25% rise in net income. Gross margins also improved by 2%, and cash flow from operations increased by 15%. These positive financial metrics, coupled with optimistic guidance for revenue growth and margin improvement, suggest a positive stock price movement. However, the lack of discussion on strategic initiatives and risks tempers the outlook slightly, leading to a 'Positive' sentiment rather than 'Strong positive.'
Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary indicates strong financial performance with a 10% revenue increase, improved gross margins, and a 25% rise in net income. Strategic initiatives focus on product innovation and market expansion, supported by favorable market trends. The positive outlook for revenue and margin improvements in 2026 further boosts sentiment. Despite potential regulatory risks, the overall tone is optimistic, suggesting a positive stock price movement over the next two weeks.
Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call presents a mixed picture: strong revenue growth and improved net income are positive, but increased operating expenses and cash position decline are concerning. The Q&A reveals uncertainties in FDA approval timelines and unclear management responses on financial guidance, which may dampen investor confidence. The company's guidance is cautious, with potential for modest revenue growth. Overall, the sentiment is balanced, leading to a neutral prediction for stock movement.
Organogenesis Holdings Inc. (ORGO) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call reveals several negative aspects: declining net product revenue, a significant EBITDA loss, and reduced cash reserves. Despite some positive notes in surgical product revenue and potential CMS reimbursement changes, the company's heavy dependence on regulatory approvals and operational risks in new facilities pose significant challenges. The Q&A section revealed reduced guidance and aggressive market behavior, further contributing to a negative sentiment. Overall, these factors suggest a negative stock price movement in the short term.
ORGO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
